Both untargeted and targeted (including 34 major known metabolites of the purines, tyrosine, and tryptophan pathways) approaches were performed to thoroughly investigate the differences between LRRK2 and idiopathic PD, as well as between controls and all PD patients. The gene discussed is LRRK2; the disease is Parkinson disease.